Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Subjects must have documented newly diagnosed symptomatic multiple myeloma requiring front-line treatment.~* Patients should be considered transplant-eligible~* Subjects will receive front-line induction therapy with a triplet regimen consisting of bortezomib, thalidomide and dexamethasone (VTD).~* To enter to the study at the same time of start anti myeloma induction therapy.~* Ages eligible for study: 18 to 70 years.~* Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.~Exclusion Criteria:~* Patients with the diagnosis of plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome or amyloidosis of light chain.~* Patients with smouldering multiple myeloma or monoclonal gammopathy of undeterminated significance.~* Patients considered non-transplant-eligible.~* Grade ≥2 of peripheral neuropathy.~* Prior history of documented any venous thromboembolism and arterial thrombosis event~* Active or high risk of bleeding.~* Need for on-going anticoagulant or antiplatelet treatment.~* Contraindication of anticoagulant prophylaxis~* Uncontrolled hypertension: systolic blood pressure \>200 mmHg and/or diastolic blood pressure \>100 mmHg.~* HIV, HBV or HCV-positive active.~* Expected survival \<6 months.~* Weight \<40 Kg.~* Low platelet count (\<50 x109/L).~* ALT \>3x UNL, bilirubin \>2x ULN.~* Creatinine clearance \<30 mL/min.~* Women of childbearing potential who are unwilling to use an acceptable method of contraception.~* Women of childbearing potential who are pregnant or breastfeeding.~* Women with a positive pregnancy test on enrollment, prior to investigational product administration.~* Administration of any investigational drug currently or within 30 days prior to planned enrollment into this study.~* Subjects unwilling or unable to comply with study medication instructions or study procedures (e.g. bilateral lower extremity venous ultrasonography).~* Known allergies to ingredients contained in apixaban.~* Use of any contraindicated medications with apixaban (see section 5.4.1).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban (single arm) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).